The role of trastuzumab deruxtecan (T-DXd) in HER2-low metastatic breast cancer treatment

Ann Oncol. 2023 Oct;34(10):948-949. doi: 10.1016/j.annonc.2023.07.004. Epub 2023 Jul 26.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Breast Neoplasms* / drug therapy
  • Camptothecin
  • Female
  • Humans
  • Immunoconjugates*
  • Receptor, ErbB-2 / genetics
  • Trastuzumab / therapeutic use

Substances

  • trastuzumab deruxtecan
  • Immunoconjugates
  • Trastuzumab
  • Camptothecin
  • Receptor, ErbB-2